RxSight, Inc. Announces Pricing of Public Offering of Common Stock - February 08, 2023
Summary
ALISO VIEJO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc. (RxSight), an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced today that it has priced its underwritten public offering. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximately $50.0 million, assuming no exercise of the underwriters option to purchase additional shares. BofA Securities is acting as the sole bookrunning manager for the offering.RxSight intends to use the net proceeds from the offering for continued commercial and marketing expansion, funding of product development, research and clinical development, and for working capital and general corporate purposes.RxSight filed a shelf registration statement on Form S-3 relating to the shares of common stock offered in the public offering described above with the Securities and Exchange Commission (the "SEC") on August 8, 2022, which was declared effective by the SEC on August 12, 2022. The RxSight\xae Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens\xae (LAL\xae), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.Forward-Looking Statements This press release contains forward-looking statements, including statements concerning expectations with respect to the expected completion and timing of closing of the public offering and the anticipated use of the net proceeds from the offering. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as may, will, should, could, would, expects, plans, intends, anticipates, believes, estimates, predicts, projects, potential, or continue or the negative of such terms and other similar terminology.